Physician profile
Daniel Benjamin Apple
NPI 1649565045
$9,890.72
in general payments reported to CMS, 2019-2025
14 companies · $502 in 2025
The $502 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,660 · 2020: $193 · 2021: $181 · 2022: $401 · 2023: $415 · 2024: $538 · 2025: $502.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.75 |
| Education | $100.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $7,801.24 | 2019-2025 | Vabysmo |
| Regeneron Healthcare Solutions, INC. | $464.98 | 2019-2025 | Eylea Hd, Eylea |
| Bausch & Lomb Americas INC. | $256.78 | 2022-2025 | Xipere, Visudyne |
| Abbvie INC. | $254.09 | 2022-2025 | Ozurdex |
| Apellis Pharmaceuticals, INC. | $215.57 | 2023-2025 | Syfovre |
| Oculus Surgical INC. | $170.96 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.81 | 2019-2021 | |
| Alimera Sciences, INC. | $138.36 | 2021-2024 | Iluvien, Yutiq |
| Astellas Pharma US INC | $133.74 | 2024-2025 | Izervay |
| Alcon Vision LLC | $109.34 | 2023 | Ngenuity |
| Allergan, INC. | $76.52 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $66.84 | 2019-2021 | |
| Ani Pharmaceuticals, INC. | $59.49 | 2025 | Iluvien, Purified Cortrophin Gel |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Apple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.